|
[1]
|
Bilimoria, K.Y., Bentrem, D.J., Ko, C.Y., Ritchey, J., Stewart, A.K., Winchester, D.P., et al. (2007) Validation of the 6th Edition AJCC Pancreatic Cancer Staging System. Cancer, 110, 738-744. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M. and Matrisian, L.M. (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 74, 2913-2921. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 364, 1817-1825. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine, 369, 1691-1703. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Gandhi, V., Legha, J., Chen, F., et al. (1996) Excision of 2’,2’-Difluorodeoxycytidine (Gemcitabine) Monophosphate Residues from DNA. Cancer Research, 56, 4453-4459.
|
|
[7]
|
Huang, W., Zeng, X., Shi, Y. and Liu, M. (2016) Functional Characterization of Human Equilibrative Nucleoside Transporter 1. Protein & Cell, 8, 284-295. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Morinaga, S., Nakamura, Y., Watanabe, T., Mikayama, H., Tamagawa, H., Yamamoto, N., et al. (2011) Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy. Annals of Surgical Oncology, 19, 558-564. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Poplin, E., Wasan, H., Rolfe, L., Raponi, M., Ikdahl, T., Bondarenko, I., et al. (2013) Randomized, Multicenter, Phase II Study of CO-101 versus Gemcitabine in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of Hent1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology, 31, 4453-4461. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Sinn, M., Riess, H., Sinn, B.V., Stieler, J.M., Pelzer, U., Striefler, J.K., et al. (2015) Human Equilibrative Nucleoside Transporter 1 Expression Analysed by the Clone SP120 Rabbit Antibody Is Not Predictive in Patients with Pancreatic Cancer Treated with Adjuvant Gemcitabine—Results from the CONKO-001 Trial. European Journal of Cancer, 51, 1546-1554. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Rauchwerger, D.R., Firby, P.S., Hedley, D.W., et al. (2000) Equilibrative-Sensitive Nucleoside Transporter and Its Role in Gemcitabine Sensitivity. Cancer Research, 60, 6075-6079.
|
|
[12]
|
Tsujie, M., Nakamori, S., Nakahira, S., Takeda, S., Takahashi, Y., Hayashi, N., et al. (2006) Schedule-Dependent Therapeutic Effects of Gemcitabine Combined with Uracil-Tegafur in a Human Pancreatic Cancer Xenograft Model. Pancreas, 33, 142-147. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Skrypek, N., Duchêne, B., Hebbar, M., Leteurtre, E., van Seuningen, I. and Jonckheere, N. (2012) The MUC4 Mucin Mediates Gemcitabine Resistance of Human Pancreatic Cancer Cells via the Concentrative Nucleoside Transporter Family. Oncogene, 32, 1714-1723. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Skrypek, N., Vasseur, R., Vincent, A., Duchêne, B., Van Seuningen, I. and Jonckheere, N. (2015) The Oncogenic Receptor ErbB2 Modulates Gemcitabine and Irinotecan/SN-38 Chemoresistance of Human Pancreatic Cancer Cells via hCNT1 Transporter and Multidrug-Resistance Associated Protein MRP-2. Oncotarget, 6, 10853-10867. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Ohhashi, S., Ohuchida, K., Mizumoto, K., et al. (2008) Down-Regulation of Deoxycytidine Kinase Enhances Acquired Resistance to Gemcitabine in Pancreatic Cancer. Anticancer Research, 28, 2205-2212.
|
|
[16]
|
Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., et al. (2012) DCK Is Frequently Inactivated in Acquired Gemcitabine-Resistant Human Cancer Cells. Biochemical and Biophysical Research Communications, 421, 98-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Maréchal, R., Mackey, J.R., Lai, R., Demetter, P., Peeters, M., Polus, M., et al. (2010) Deoxycitidine Kinase Is Associated with Prolonged Survival after Adjuvant Gemcitabine for Resected Pancreatic Adenocarcinoma. Cancer, 116, 5200-5206. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Nakahira, S., Nakamori, S., Tsujie, M., Takahashi, Y., Okami, J., Yoshioka, S., et al. (2006) Involvement of Ribonucleotide Reductase M1 Subunit Overexpression in Gemcitabine Resistance of Human Pancreatic Cancer. International Journal of Cancer, 120, 1355-1363. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Ying, H., Kimmelman, A.C., Bardeesy, N., et al. (2025) Genetics and Biology of Pancreatic Ductal Adenocarcinoma. Genes & Development, 39, 36-63.
|
|
[20]
|
Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., et al. (2021) BRCA-Mutant Pancreatic Ductal Adenocarcinoma. British Journal of Cancer, 125, 1321-1332. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Calheiros, J., Silva, R., Barbosa, F., Morais, J., Moura, S.R., Almeida, S., et al. (2025) A First-in-Class Inhibitor of Homologous Recombination DNA Repair Counteracts Tumour Growth, Metastasis and Therapeutic Resistance in Pancreatic Cancer. Journal of Experimental & Clinical Cancer Research, 44, Article No. 129. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Lu, H., Lu, S., Yang, D., Zhang, L., Ye, J., Li, M., et al. (2019) MiR-20a-5p Regulates Gemcitabine Chemosensitivity by Targeting RRM2 in Pancreatic Cancer Cells and Serves as a Predictor for Gemcitabine-Based Chemotherapy. Bioscience Reports, 39, BSR20181374. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Chen, L., Huan, X., Gao, X., Yu, W., Xiao, G., Li, T., et al. (2022) Biological Functions of the DNA Glycosylase NEIL3 and Its Role in Disease Progression Including Cancer. Cancers, 14, Article No. 5722. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Visnes, T., Grube, M., Hanna, B.M.F., Benitez-Buelga, C., Cázares-Körner, A. and Helleday, T. (2018) Targeting BER Enzymes in Cancer Therapy. DNA Repair, 71, 118-126. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Gohil, D., Sarker, A.H. and Roy, R. (2023) Base Excision Repair: Mechanisms and Impact in Biology, Disease, and Medicine. International Journal of Molecular Sciences, 24, Article No. 14186. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Bapat, A., Fishel, M.L. and Kelley, M.R. (2009) Going Ape as an Approach to Cancer Therapeutics. Antioxidants & Redox Signaling, 11, 651-667. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Fishel, M.L. and Kelley, M.R. (2007) The DNA Base Excision Repair Protein Ape1/Ref-1 as a Therapeutic and Chemopreventive Target. Molecular Aspects of Medicine, 28, 375-395. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Kelley, M.R., Logsdon, D. and Fishel, M.L. (2014) Targeting DNA Repair Pathways for Cancer Treatment: What’s New? Future Oncology, 10, 1215-1237. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Pramanik, S., Chen, Y., Song, H., Khutsishvili, I., Marky, L.A., Ray, S., et al. (2022) The Human Ap-Endonuclease 1 (APE1) Is a DNA G-Quadruplex Structure Binding Protein and Regulates KRAS Expression in Pancreatic Ductal Adenocarcinoma Cells. Nucleic Acids Research, 50, 3394-3412. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts, D.J., Lauwers, G.Y., et al. (2003) Hedgehog Is an Early and Late Mediator of Pancreatic Cancer Tumorigenesis. Nature, 425, 851-856. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Bailey, J.M., Swanson, B.J., Hamada, T., Eggers, J.P., Singh, P.K., Caffery, T., et al. (2008) Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer. Clinical Cancer Research, 14, 5995-6004. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., et al. (2008) Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 321, 1801-1806. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Bahra, M., Kamphues, C., Boas-Knoop, S., Lippert, S., Esendik, U., Schüller, U., et al. (2012) Combination of Hedgehog Signaling Blockage and Chemotherapy Leads to Tumor Reduction in Pancreatic Adenocarcinomas. Pancreas, 41, 222-229. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Huang, F., Zhuan-Sun, Y., Zhuang, Y., Wei, S., Tang, J., Chen, W., et al. (2012) Inhibition of Hedgehog Signaling Depresses Self-Renewal of Pancreatic Cancer Stem Cells and Reverses Chemoresistance. International Journal of Oncology, 41, 1707-1714. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Xu, M., Li, L., Liu, Z., Jiao, Z., Xu, P., Kong, X., et al. (2013) ABCB2 (TAP1) as the Downstream Target of SHH Signaling Enhances Pancreatic Ductal Adenocarcinoma Drug Resistance. Cancer Letters, 333, 152-158. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Arlt, A., Gehrz, A., Müerköster, S., Vorndamm, J., Kruse, M., Fölsch, U.R., et al. (2003) Role of NF-κB and Akt/PI3K in the Resistance of Pancreatic Carcinoma Cell Lines against Gemcitabine-Induced Cell Death. Oncogene, 22, 3243-3251. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Pan, X., Arumugam, T., Yamamoto, T., Levin, P.A., Ramachandran, V., Ji, B., et al. (2008) Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Clinical Cancer Research, 14, 8143-8151. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Dilly, J., Hoffman, M.T., Abbassi, L., Li, Z., Paradiso, F., Parent, B.D., et al. (2024) Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discovery, 14, 2135-2161. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Réjiba, S., Wack, S., Aprahamian, M. and Hajri, A. (2007) K-Ras Oncogene Silencing Strategy Reduces Tumor Growth and Enhances Gemcitabine Chemotherapy Efficacy for Pancreatic Cancer Treatment. Cancer Science, 98, 1128-1136. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Mendt, M., Kamerkar, S., Sugimoto, H., McAndrews, K.M., Wu, C., Gagea, M., et al. (2018) Generation and Testing of Clinical-Grade Exosomes for Pancreatic Cancer. JCI Insight, 3, e99263. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Manning, B.D. and Cantley, L.C. (2007) AKT/PKB Signaling: Navigating Downstream. Cell, 129, 1261-1274. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Liu, T., Fang, Y., Zhang, H., Deng, M., Gao, B., Niu, N., et al. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Research, 76, 572-581. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Pal, S.K., Reckamp, K., Yu, H. and Figlin, R.A. (2010) Akt Inhibitors in Clinical Development for the Treatment of Cancer. Expert Opinion on Investigational Drugs, 19, 1355-1366. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Roberts, P.J. and Der, C.J. (2007) Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of Cancer. Oncogene, 26, 3291-3310. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Guo, Y.J., Pan, W.W., Liu, S.B., Shen, Z., Xu, Y. and Hu, L. (2020) ERK/MAPK Signalling Pathway and Tumorigenesis (Review). Experimental and Therapeutic Medicine, 19, 1997-2007. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
García-Gómez, R., Bustelo, X.R. and Crespo, P. (2018) Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway. Trends in Cancer, 4, 616-633. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Khotskaya, Y.B., Holla, V.R., Farago, A.F., Mills Shaw, K.R., Meric-Bernstam, F. and Hong, D.S. (2017) Targeting TRK Family Proteins in Cancer. Pharmacology & Therapeutics, 173, 58-66. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
McDaid, H.M., Lopez-Barcons, L., Grossman, A., Lia, M., Keller, S., Pérez-Soler, R., et al. (2005) Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants. Cancer Research, 65, 2854-2860. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Kim, M., Yan, Y., Kortum, R.L., Stoeger, S.M., Sgagias, M.K., Lee, K., et al. (2005) Expression of Kinase Suppressor of Ras1 Enhances Cisplatin-Induced Extracellular Signal-Regulated Kinase Activation and Cisplatin Sensitivity. Cancer Research, 65, 3986-3992. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Chang, G.C., Hsu, S.L., Tsai, J.R., Wu, W., Chen, C. and Sheu, G. (2004) Extracellular Signal-Regulated Kinase Activation and Bcl-2 Downregulation Mediate Apoptosis after Gemcitabine Treatment Partly via a p53-Independent Pathway. European Journal of Pharmacology, 502, 169-183. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Zhao, Y., Shen, S., Guo, J., Chen, H., Yu Greenblatt, D., Kleeff, J., et al. (2006) Mitogen-Activated Protein Kinases and Chemoresistance in Pancreatic Cancer Cells. Journal of Surgical Research, 136, 325-335. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Mahato, R., Kumar, V., Sethi, B., et al. (2023) Gemcitabine Elaidate and ONC201 Combination Therapy Inhibits Pancreatic Cancer in a KRAS Mutated Syngeneic Mouse Model. Research Square, rs.3.rs-3108907.
|
|
[53]
|
Zhang, H., Wu, H., Guan, J., Wang, L., Ren, X., Shi, X., et al. (2014) Paracrine SDF-1α Signaling Mediates the Effects of PSCs on GEM Chemoresistance through an IL-6 Autocrine Loop in Pancreatic Cancer Cells. Oncotarget, 6, 3085-3097. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Liu, Y., Li, F., Gao, F., Xing, L., Qin, P., Liang, X., et al. (2016) Periostin Promotes the Chemotherapy Resistance to Gemcitabine in Pancreatic Cancer. Tumor Biology, 37, 15283-15291. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Cao, F., Li, J., Sun, H., Liu, S., Cui, Y. and Li, F. (2015) HES 1 Is Essential for Chemoresistance Induced by Stellate Cells and Is Associated with Poor Prognosis in Pancreatic Cancer. Oncology Reports, 33, 1883-1889. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Delitto, D., Black, B.S., Sorenson, H.L., Knowlton, A.E., Thomas, R.M., Sarosi, G.A., et al. (2015) The Inflammatory Milieu within the Pancreatic Cancer Microenvironment Correlates with Clinicopathologic Parameters, Chemoresistance and Survival. BMC Cancer, 15, Article No. 783. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Firuzi, O., Che, P.P., El Hassouni, B., Buijs, M., Coppola, S., Löhr, M., et al. (2019) Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers, 11, Article No. 638. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Mitchem, J.B., Brennan, D.J., Knolhoff, B.L., Belt, B.A., Zhu, Y., Sanford, D.E., et al. (2013) Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. Cancer Research, 73, 1128-1141. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Song, X., Liu, X., Chi, W., Liu, Y., Wei, L., Wang, X., et al. (2006) Hypoxia-Induced Resistance to Cisplatin and Doxorubicin in Non-Small Cell Lung Cancer Is Inhibited by Silencing of HIF-1α Gene. Cancer Chemotherapy and Pharmacology, 58, 776-784. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Yokoi, K. and Fidler, I.J. (2004) Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine. Clinical Cancer Research, 10, 2299-2306. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Deng, D., Patel, R., Chiang, C. and Hou, P. (2022) Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance. Cells, 11, Article No. 2952. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Wang, R., Cheng, L., Xia, J., Wang, Z., Wu, Q. and Wang, Z. (2014) Gemcitabine Resistance Is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells. Current Cancer Drug Targets, 14, 407-417. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Shukla, S.K., Purohit, V., Mehla, K., Gunda, V., Chaika, N.V., Vernucci, E., et al. (2017) MUC1 and HIF-1α Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell, 32, Article No. 392. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Ding, J., Xie, Y., Liu, Z., Zhang, Z., Ni, B., Yan, J., et al. (2025) Hypoxic and Acidic Tumor Microenvironment-Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex. Gastroenterology, 168, 539-555.e5. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Eltzschig, H.K., Abdulla, P., Hoffman, E., Hamilton, K.E., Daniels, D., Schönfeld, C., et al. (2005) HIF-1-Dependent Repression of Equilibrative Nucleoside Transporter (ENT) in Hypoxia. The Journal of Experimental Medicine, 202, 1493-1505. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Morote-Garcia, J.C., Rosenberger, P., Nivillac, N.M.I., Coe, I.R. and Eltzschig, H.K. (2009) Hypoxia-Inducible Factor-dependent Repression of Equilibrative Nucleoside Transporter 2 Attenuates Mucosal Inflammation during Intestinal Hypoxia. Gastroenterology, 136, 607-618. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Singh, M., Yelle, N., Venugopal, C. and Singh, S.K. (2018) EMT: Mechanisms and Therapeutic Implications. Pharmacology & Therapeutics, 182, 80-94. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Arumugam, T., Ramachandran, V., Fournier, K.F., Wang, H., Marquis, L., Abbruzzese, J.L., et al. (2009) Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research, 69, 5820-5828. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., et al. (2015) Epithelial-to-Mesenchymal Transition Is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer. Nature, 527, 525-530. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Rodriguez-Aznar, E., Wiesmüller, L., Sainz, B. and Hermann, P.C. (2019) EMT and Stemness—Key Players in Pancreatic Cancer Stem Cells. Cancers, 11, Article No. 1136. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Takemura, K., Ikeda, K., Miyake, H., Sogame, Y., Yasuda, H., Okada, N., et al. (2025) Epithelial-Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells. Biomolecules, 15, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Amponsah, P.S., Fan, P., Bauer, N., Zhao, Z., Gladkich, J., Fellenberg, J., et al. (2017) microRNA-210 Overexpression Inhibits Tumor Growth and Potentially Reverses Gemcitabine Resistance in Pancreatic Cancer. Cancer Letters, 388, 107-117. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Iliopoulos, D. and Drakaki, A. (2013) MicroRNA-Gene Signaling Pathways in Pancreatic Cancer. Biomedical Journal, 36, 200-208. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Jiao, F., Hu, H., Han, T., Yuan, C., Wang, L., Jin, Z., et al. (2015) Long Noncoding RNA MALAT-1 Enhances Stem Cell-Like Phenotypes in Pancreatic Cancer Cells. International Journal of Molecular Sciences, 16, 6677-6693. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Kim, K., Jutooru, I., Chadalapaka, G., Johnson, G., Frank, J., Burghardt, R., et al. (2012) HOTAIR Is a Negative Prognostic Factor and Exhibits Pro-Oncogenic Activity in Pancreatic Cancer. Oncogene, 32, 1616-1625. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Wang, L., Dong, P., Wang, W., Huang, M. and Tian, B. (2017) Gemcitabine Treatment Causes Resistance and Malignancy of Pancreatic Cancer Stemlike Cells via Induction of lncRNA HOTAIR. Experimental and Therapeutic Medicine, 14, 4773-4780. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Ferreira, H.J. and Esteller, M. (2018) CpG Islands in Cancer: Heads, Tails, and Sides. In: Vavouri, T. and Peinado, M.A., Eds., CpG Islands, Springer, 49-80. [Google Scholar] [CrossRef] [PubMed]
|
|
[78]
|
Luan, J., Gao, X., Hu, F., Zhang, Y. and Gou, X. (2019) SLFN11 Is a General Target for Enhancing the Sensitivity of Cancer to Chemotherapy (DNA-Damaging Agents). Journal of Drug Targeting, 28, 33-40. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Tang, S., Thomas, A., Murai, J., Trepel, J.B., Bates, S.E., Rajapakse, V.N., et al. (2018) Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors. Clinical Cancer Research, 24, 1944-1953. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Yang, L., Wang, R. and Zhang, L. (2025) HSPB1/KDM1 a Facilitates ANXA2 Expression via Hypomethylated DNA Promoter to Inhibit Ferroptosis and Enhance Gemcitabine Resistance in Pancreatic Cancer. Naunyn-Schmiedeberg’s Archives of Pharmacology, 398, 15665-15681. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Liu, Z.D., Shi, Y.H., Xu, Q.C., Zhao, G., Zhu, Y., Li, F., et al. (2024) CSNK2A1 Confers Gemcitabine Resistance to Pancreatic Ductal Adenocarcinoma via Inducing Autophagy. Cancer Letters, 585, Article ID: 216640. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Bjånes, T.K., Jordheim, L.P., Schjøtt, J., Kamceva, T., Cros-Perrial, E., Langer, A., et al. (2020) Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. Drug Metabolism and Disposition, 48, 153-158. [Google Scholar] [CrossRef] [PubMed]
|
|
[83]
|
Yin, T., Wei, H., Gou, S., Shi, P., Yang, Z., Zhao, G., et al. (2011) Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine. International Journal of Molecular Sciences, 12, 1595-1604. [Google Scholar] [CrossRef] [PubMed]
|
|
[84]
|
Makena, M.R., Ranjan, A., Thirumala, V. and Reddy, A.P. (2020) Cancer Stem Cells: Road to Therapeutic Resistance and Strategies to Overcome Resistance. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1866, Article ID: 165339. [Google Scholar] [CrossRef] [PubMed]
|
|
[85]
|
Papa, A., Basu, S., Sengupta, P., Banerjee, D., Sengupta, S. and Harfouche, R. (2012) Mechanistic Studies of Gemcitabine-Loaded Nanoplatforms in Resistant Pancreatic Cancer Cells. BMC Cancer, 12, Article No. 419. [Google Scholar] [CrossRef] [PubMed]
|
|
[86]
|
Birhanu, G., Javar, H.A., Seyedjafari, E. and Zandi-Karimi, A. (2017) Nanotechnology for Delivery of Gemcitabine to Treat Pancreatic Cancer. Biomedicine & Pharmacotherapy, 88, 635-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[87]
|
Yang, M., Li, J., Gu, P. and Fan, X. (2021) The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment. Bioactive Materials, 6, 1973-1987. [Google Scholar] [CrossRef] [PubMed]
|